CML is driven by the BCR-ABL fusion oncogene and treatment with the tyrosine kinase inhibitor imatinib results in lasting remission for the vast majority of patients. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.